DPP1 Inhibitor Shows Promise in Non-CF Bronchiectasis |
Journal Updates
eMediNexus Coverage from: 
DPP1 Inhibitor Shows Promise in Non-CF Bronchiectasis

0 Read Comments                

Treatment with the investigational anti-inflammatory drug brensocatib led to significant delay in the time to exacerbation in patients with non-cystic fibrosis bronchiectasis, suggested new research.

Phase II results from the multicenter WILLOW trial, including 256 adults with at least two documented bronchiectasis exacerbations over the past year, revealed that both doses of the oral drug tested (10 and 25 mg/day) delayed the time to first pulmonary exacerbation over the 24-week treatment period compared with placebo. The findings were presented at an American Thoracic Society (ATS) 2020 virtual session… (Medpage Today)

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now